Staphylococcus aureus can cause a variety of infections, many of which involve biofilm infections. Inside 15 biofilms, growing and non-growing bacteria such as persisters co-exist, making it challenging to completely 16 eradicate a persistent and recurrent infection with current treatments. Despite the clinical relevance, most of the 17 current antibiotic treatments mainly kill the growing bacteria and have poor activity against non-growing 18 persister bacteria and thus have limited effect on treating persistent infections including biofilm infections. We 19 previously proposed a Yin-Yang model using a drug combination approach targeting both growing bacteria and 20 persister bacteria for more effective clearance of persistent infections. Here, as a proof of principle, we showed 21 that combining drugs that have high activity against growing forms, such as vancomycin or meropenem, with 22 drugs that have robust anti-persister activity, such as clinafloxacin and oritavancin, could completely eradicate S. 23 aureus biofilm bacteria in vitro. In contrast, single or two drugs including the current treatment for persistent S. 24 aureus infection doxycycline plus rifampin failed to kill all biofilm bacteria in vitro. We then developed a 25 chronic persistent skin infection mouse model with biofilm-seeded bacterial inocula demonstrating that biofilm 26 bacteria caused more severe and persistent skin lesions than log phase S. aureus bacteria. More importantly, we 27 found that the drug combination which eradicated biofilm bacteria in vitro is more efficacious than current 28 treatments and completely eradicated S. aureus biofilm infection in mice. The complete eradication of biofilm 29 bacteria is attributed to the unique high anti-persister activity of clinafloxacin, which could not be replaced by 30 other fluoroquinolones such as moxifloxacin, levofloxacin or ciprofloxacin. Our study is the first to demonstrate 31 that the combination of meropenem, daptomycin, plus clinafloxacin completely cleared the persistent infection, 32 healed the lesions, and had less inflammation, while mice treated with doxycycline plus rifampin, the current 33 clinically recommended treatment for chronic tissue infection, failed to do so. We also compared our persister 34 drug combination with other approaches for treating persistent infections including gentamicin+fructose and 35 ADEP4+rifampin in the S. aureus biofilm infection mouse model. Neither gentamicin+fructose nor 36 ADEP4+rifampin could eradicate or cure the persistent biofilm infection in mice. In contrast, our drug 37 combination regimen with persister drug clinafloxacin plus meropenem and daptomycin completely eradicated 38 and cured the persistent biofilm infection in 7 days. An unexpected observation is that ADEP4 treatment group 39 developed worsened skin lesions and caused more extensive pathology than the untreated control mice. Our 40 study demonstrates an important treatment principle for persistent infections by targeting both growing and non-41 growing heterogeneous bacterial populations utilizing persister drugs for more effective eradication of persistent 42 and biofilm infections. Our findings may have implications for improved treatment of many other persistent 43 infections in general. 44 45 46 47
Introduction
While vancomycin is highly effective in killing MRSA bacteria in vitro, monotherapy with vancomycin may 04 not be the most effective in clearing chronic infections with S. aureus. For conditions such as osteomyelitis and 05 prosthetic joint infections, treatment with vancomycin as a monotherapy or drug combination for at least 6 06 weeks are recommended. Drug combination such as doxycycline + rifampin for up to 10 days, vancomycin + 07 gentamicin + rifampin for at least 6 weeks are recommended to treat chronic infections such as recurrent tissue 08 infections and endocarditis on prosthetic valves, respectively (The Johns Hopkins Antibiotics Guide). We first 09 evaluated the activity of the above drugs in killing biofilm bacteria in vitro using traditional bacterial cell counts 10 ( Fig. 1A) , viability assessment by SYBR Green I/Propidium Iodide staining that has been developed to screen 11 for drugs targeting borrelia persister bacteria 28 (Fig. 1B) , and staining of absolute biofilm (Fig. 1C-G) . We 12 found that such clinically used combinations are not completely effective against biofilms. After 4-day 13 treatment, biofilm bacteria were not completely eradicated by any of current treatments with vancomycin alone, 14 or doxycycline + rifampin or vancomycin+gentamicin+rifampin as shown by significant numbers of bacteria 15 remaining ( Fig. 1 ). However, it is worth noting that vancomycin+gentamicin+rifampin was more active than 16 vancomycin alone or doxycycline + rifampin in killing biofilm bacteria ( Fig. 1A ).
18
Identification of drug combinations with strong anti-biofilm activity 19 20 To address the clinical unmet need of better treatments against persistent infections, we hypothesize that a drug 21 combination that includes drugs that act on growing bacteria such as cell wall (e.g. vancomycin, meropenem) or 22 cell membrane inhibitors (e.g. daptomycin) plus a drug that acts on persister bacteria will be a more potent drug 23 combination in eradicating biofilm bacteria. Previous studies from our lab identified tosufloxacin and 24 clinafloxacin as having strong anti-persister activity against S. aureus 27 . In order to identify a potent 25 combination, we tested various drug combinations that include drugs against both growing bacteria and non-26 growing persisters in an in vitro biofilm model. Biofilms of S. aureus strain USA300, a common circulating 27 strain of community acquired-MRSA (CA-MRSA), were grown in 96-well microtiter plates to allow biofilm 28 formation on the bottom of the wells 29 . While we previously showed that tosufloxacin had robust activity 29 against S. aureus persister cells, drug combination of vancomycin/meropenem + daptomycin + tosufloxacin 30 achieved only partial eradication, with 10 5 CFU/ml in biofilms remaining after treatment ( Fig. 2A-B ). In 31 contrast, combination of vancomycin/meropenem + daptomycin + clinafloxacin showed absolute eradication of 32 biofilms after 4-day treatment as shown by 0 CFU and a live/dead ratio below the limit of detection ( Fig. 2A- 
33
B). Although we used the same molar concentration of each drug (50 μM of each drug) in our drug screen for 34 comparison of relative drug activity, to evaluate the activity of the combination in a more clinically relevant 35 manner, we treated the biofilms with the drugs at their Cmax concentrations (Table 1) . Our findings with Cmax 36 drug concentrations were confirmatory as the combination of vancomycin/meropenem + daptomycin + 37 clinafloxacin still achieved complete eradication while our no treatment control and the clinically used We then tested the potential of the drug combination of meropenem + daptomycin + clinafloxacin to eradicate 42 biofilm bacteria from different MRSA S. aureus strains, including other CA-MRSA clinical isolates CA-409, 43 CA-127, and hospital-acquired MRSA strain GA-656. Complete eradication (0 CFU/ml) and undetectable 44 levels of live cells (under the limit of detection) were found for all of the MRSA strains tested after 4 days of 45 treating biofilms with our combination meropenem + daptomycin + clinafloxacin ( Fig. 2E-F ).
47
Unique anti-persister activity of clinafloxacin that could not be replaced by other fluoroquinolone drugs
Clinafloxacin is a member of the fluoroquinolone class of antibiotics which inhibits DNA replication by binding 50 to DNA gyrase. As our results suggest ( Fig. 1 ), clinafloxacin is a powerful anti-persister drug. We then wanted 51 to rank the anti-biofilm activity of different fluoroquinolones to determine whether the robust anti-biofilm 52 activity of clinafloxacin used in combination is unique to the drug itself or can be replaced by other members of 53 fluoroquinolone antibiotics. To do so, we used the S. aureus Newman strain due to its susceptibility to many 54 fluoroquinolones as we wanted to eliminate any confounding factors due to inherent drug resistance. While 55 other fluoroquinolones such as ciprofloxacin, levofloxacin, and moxifloxacin had certain anti-persister or anti-56 biofilm activity when used in combination with meropenem and daptomycin after 4-days of treatment, the drug 57 combination with clinafloxacin was indeed the most active and was the only combination that achieved 58 complete sterilization. By contrast, biofilms treated with combinations consisting of other quinolones still 59 harbored 10 4 -10 8 CFU/ml. When used in combination, the activity of the quinolones from strongest to weakest 60 as ranked by both viability assessment and viable cell counts is as follows: clinafloxacin, ciprofloxacin, 61 moxifloxacin, and levofloxacin (Table 2 ). Hence, clinafloxacin has unique potent activity against persisters 62 compared to other fluoroquinolone counterparts.
64
Anti-persister activity of oritavancin and dalbavancin 65 66
Thus far, our data suggest that inclusion of a drug with great anti-persister activity can be beneficial in killing 67 biofilm bacteria ( Fig. 1, Fig. 2 , and Table 2 ). To identify other potential anti-persister candidates, we turned to 68 the new generation of lipoglycopeptides such as oritavancin and dalbavancin. These drugs have multiple 69 mechanisms of action: inhibition of transglycosylation, transpeptidation, and cell membrane disruption, a 70 property of persister drugs 19 .We first tested the activity of oritavancin and dalbavancin in killing S. aureus 71 persisters in comparison with its parent counterpart vancomycin, and the results revealed oritavancin was the 72 best in killing persisters among the three drugs ( Fig. 3A ). After 6-day drug exposure, oritavancin killed 10 6 73 CFU/ml of persisters as compared with dalbavancin or vancomycin which killed only about 10 2 CFU/ml.
75
Since oritavancin showed strong anti-persister activity, we next evaluated oritavancin's activity in drug 76 combinations. After replacing clinafloxacin with oritavancin, we observed that the combination of meropenem 77 + daptomycin + oritavancin exhibited partial activity against biofilms, a decrease of 10 5 CFU/ml, which is much 78 better than the activity achieved by treatment with single drugs or two-drug combinations, but still inferior to 79 the clinafloxacin combination ( Fig. 3B ).
81
Due to oritavancin's strong activity against growing phase S. aureus (MIC of 0.03 mg/L) 30 and its dual 82 mechanism of action that mimics cell wall + cell membrane inhibitors in our drug combination, we tested 83 oritavancin in place of meropenem and daptomycin. Surprisingly, the combination of oritavancin + 84 clinafloxacin was also able to achieve complete eradication of biofilms suggesting that oritavancin can replace 85 the component in our drug combination that targets actively growing bacteria ( Fig. 3C ). It is also important to 86 note that single drug of oritavancin cannot kill biofilms (no change in CFU after 4 day treatment) which further 87 validates the importance of drug combinations in biofilm bacteria.
89
To compare the activity of the three combinations tested thus far with clinafloxacin, we performed a time-90 course kill experiment which revealed that oritavancin + clinafloxacin can kill all biofilms by 2-day treatment 91 whereas it took 4 days for meropenem/vancomycin + daptomycin + clinafloxacin to eradicate the biofilm 92 bacteria ( Fig. 3D ). Overall, our data suggest that inclusion of an anti-persister drug in a drug combination to 93 treat biofilms is paramount and these combinations possess better activity than current clinically used regimens 94 based on our in vitro studies.
96
The drug combination meropenem + daptomycin +clinafloxacin eradicated biofilm infections in the mouse skin 97 persistent infection model 98 99
Given the robust activity of our drug combinations in eradicating biofilms in vitro, we were interested to know 00 if our combination can also eradicate persistent infections in-vivo. To evaluate the efficacy of our drug 01 combinations in treating the persistent skin infection, we chose to infect mice with biofilm bacteria from S. 02 aureus strain USA300, a clinical strain most representative to causing persistent infections in a host. We 03 allowed the infection to develop for 7 days, followed by 7 day treatment with different regimens (Fig. 4A ).
04
Previously, we have shown that mice infected with biofilm bacteria developed more chronic skin lesions 31 .
05
Administration of the combination of doxycycline + rifampin (a control group as a clinically used treatment) or 06 drug combination vancomycin + daptomycin + clinafloxacin decreased the bacteria load (about 1-log of bacteria) 07 but did not clear the infection (Fig. 4B ). Other treatments which supposedly eradicate chronic S. aureus 08 infections such as ADEP4+rifampin 32 or frustose+gentamicin 33 did not show sterilizing activity in our biofilm 09 infection model and instead, had increased lesion size and inflammation ( Fig. 4C ). Remarkably, our 10 combination of meropenem + daptomycin + clinafloxacin cleared the infection completely, decreased the size 11 of lesions, and reduced histopathology scores, and healed the lesions completely ( Fig. 4D -G).
13
Because our in-vivo experiments were done using an MRSA strain USA300, we wanted to infect mice with a 14 methicillin susceptible S. aureus Newman strain (MSSA) to ensure that our drug combination is effective for 15 other S. aureus strains. In addition, we wanted to further confirm that clinafloxacin's activity, compared to other Numerous studies have documented how resilient biofilms and biofilm infections are to antibiotic treatments 35-37 37 . Since persister cells that are embedded in the biofilm are mostly responsible for recalcitrance of biofilms to 38 antibiotic treatments, many attempts have been made to identify novel treatments and synthetic compounds that 39 kill bacterial persisters 38, 39 . Some approaches include resuscitating or altering the metabolic status of persisters animal models, however, in this study, we showed that biofilm inocula produced a more severe lesion and more 48 persistent infection than the log phase bacteria 31 . This biofilm-inocula model could serve as a useful model for 49 evaluating treatment regimens against biofilm infections in vivo in general. Importantly, we were able to show 50 that single drugs or even two drug combinations can this study, to identify more effective regimens to treat 51 chronic S. aureus infections, we first identified several drug combinations that are more active in killing 52 biofilms in vitro than currently recommended regimens (e.g. vancomycin alone, doxycycline + rifampin, and 53 vancomycin + gentamicin + rifampin) used clinically. Then, we confirmed the potent activity of the 54 combination meropenem + daptomycin + clinafloxacin in our newly established chronic, skin infection mouse 55 model.
57
Previously, we identified both clinafloxacin and tosufloxacin as having robust activity against S. aureus 58 persisters 27 . However, in our drug combination studies, clinafloxacin used in combination displayed greater 59 activity against biofilms than tosufloxacin. This could potentially be explained by the genetic background and 60 inherent antibiotic resistance of the strain tested. Previously, tosufloxacin was identified to have great persister 61 activity in the background of the Newman strain 27 , a methicillin-sensitive S. aureus strain whereas our biofilm 62 experiments conducted here used USA300, a MRSA strain. The ability between these strains to form biofilms 63 may also be a contributing factor 43 . Nonetheless, despite being unable to achieve complete eradication, it must 64 be noted that inclusion of any anti-persister drug in combination (clinafloxacin, tosufloxacin, or oritavancin) 65 with drugs that can kill growing bacteria can kill more bacteria in biofilms than currently approved regimens, 66 confirming the importance of targeting the heterogeneous of bacterial populations in developing more effective 67 treatments.
69
We showed that meropenem + daptomycin + clinafloxacin achieved sterilizing activity in a chronic, skin having native or prosthetic valve endocarditis also showed that clinafloxacin was an effective treatment 49 . As a 80 quinolone, clinafloxacin inhibits bacterial DNA gyrase and topoisomerase IV but not all quinolones have anti-81 persister activity (Table 1) . Comparing the chemical structure of clinafloxacin to the other quinolones that have 82 weak anti-persister activity (ciprofloxacin, tosufloxacin, moxifloxacin, and levofloxacin), a chloride group 83 attached to the benzene ring appears to be unique to only clinafloxacin (Fig. 6 ). Further studies to explore the 84 mechanism of clinafloxacin's unique ability to kill persisters requires further investigation.
86
While meropenem and daptomycin are our agents directed at killing growing bacteria, it is important to note 87 that these drugs also have some activity against persisters. Meropenem used in combination with polymyxin B 88 has been shown to eradicate persisters in Acinetobacter baumannii strains 50 . Similarly, daptomycin has been 89 shown to be active against S. aureus biofilms found on implants 51 . Daptomycin in combination with 90 doxycycline and cefoperazone or cefuroxime have been shown to kill biofilm-like microcolonies of B. 91 burgdorferi 26,52 . Its mechanism of action in disrupting membrane structure and rapid depolarization of the 92 membrane may impact the viability of persisters and thus, play an important role in the combination 53 .
94
It is important to note that the chronic infection status of our mice is a key component to our disease model. The and infection allowed to develop for 1 week before treatment. The combination of an aminoglycoside + sugar 03 was shown to be effective in an E. coli urinary tract infection model 33 but unfortunately this approach was not 04 effective in our biofilm infection model either. Allison et al. showed that gentamicin + fructose reduced 1.5 fold 05 of S. aureus biofilms in vitro after 4 hours of treament 33 but was not tested in animals. In our study here, we 06 showed that mice treated for 7 days with gentamicin + fructose still harbored 10 5 CFU/ml in skin tissues and 07 showed an increase in lesion size despite the treatment. In both these cases, the discrepancy could be due to 08 differences in the disease model, as ours is a more persistent biofilm skin infection model established with 09 biofilm inocula and would be expected to be more difficult to cure than the other studies that did not use biofilm 10 inocula for the infection.
12
Our combination of meropenem + daptomycin + clinafloxacin showed sterilizing activity in mice after one 13 week based on the concentrations of drugs and dosing regimens commonly found in literature (Table 2) . Higher, 14 yet safe, concentrations of drugs should be tested to see whether or not a shorter treatment period can achieve 15 similar eradication, which would be beneficial for patients undergoing therapy. Further PK/PD studies of our 16 drug combination are needed. Moreover, meropenem, daptomycin, and clinafloxacin are intravenous drugs and 17 not convenient to administer. Future studies to develop oral regimens as effective as the identified combinations 18 are needed for more convenient administration. Our in vitro data suggested that oritavancin used in combination 19 with clinafloxacin had robust activity against biofilms, killing all the bacteria in the biofilms (10 7 CFU) after a 20 short treatment of 2 days. The administration of oritavancin is a single 1200-mg dose given in a slow, 3 hour 21 infusion, which may also be of interest for patients due to the ease of administration and long half-life. Hence, 22 preclinical studies in mice to test oritavancin's activity in chronic infections need to be performed carefully.
24
Currently used regimens for treating persistent infections are lengthy and the inability to clear the bacteria in a 25 timely fashion may also increase the chances of developing antibiotic resistance. A drug combination that has 
59
To determine the cell and biofilm density, the supernatant was removed from the well and the biofilms were 60 washed twice with PBS (1X). To enumerate bacterial cell counts, the biofilms in the wells were resuspended in 61 TSB and scraped with a pipette tip before serial dilution and plating. To assess cell viability using the ratio of 62 green:red fluorescence to determine the ratio of live:dead cells, respectively, the biofilms were stained with 63 SYBR Green I/Propidium Iodide dyes as described 28, 54 . Briefly, SYBR Green I (10,000× stock) was mixed 64 with PI (20 mM) in distilled H 2 O at a ratio of 1:3, respectively. The SYBR Green I/PI staining mix was added 65 to each sample at a ratio of 1:10 (10 µl of dye for 100 µl of sample). Upon incubation at room temperature in 66 the dark for 20 min, the green and red fluorescence intensity was detected using a Synergy H1 microplate reader 67 by BioTek Instruments (Winooski, VT, USA) at excitation wavelength of 485 nm and 538 nm and 612 nm for 68 green and red emission, respectively. To visualize biofilm biomass, biofilms were stained with crystal violet 69 (0.1%) for 15 minutes at room temperature. Excess dyes were washed with water and the biofilms were left to 70 air dry. Images were recorded using Keyence BZ-X710 microscope and were processed using BZ-X Analyzer 71 software provided by Keyence (Osaka, Japan). 
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